InsidersTradesSigma
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
12
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+12.0%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Chan Phillip P., Chief Executive Officer. Officer active across 1 company, notably Cytosorbents Corp. In total, 18 reports have been recorded. Breakdown: 12 buys · 0 sell. Total volume traded: €260k. Activity tracked since 10 December 2021. The latest transaction was disclosed on 24 February 2025 (O). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
251,136 sharesCommon StockSEC:0001104659-26-074164:0
Ideal exit: 9 Mar 2027 (T+270)
10,333 sharesCommon StockSEC:0001104659-26-074164:1
Ideal exit: 12 Mar 2027 (T+270)
34,168 shares@ US$1.137.9% of flowCommon StockSEC:0001104659-25-017619:0
90,832 shares@ US$1.0018.9% of flowCommon StockSEC:0001104659-25-005353:0
96,000 shares0Common StockSEC:0001104659-24-043788:0
75,188 shares@ US$1.3319.9% of flowCommon StockSEC:0001104659-23-126421:0
Ideal exit: 8 Sept 2024 (T+270)
87,000 shares0Common StockSEC:0001104659-23-080105:0
30,500 shares@ US$2.87517.3% of flowCommon StockSEC:0001104659-23-042221:0
5,859 shares@ US$1.261.5% of flowCommon StockSEC:0001104659-22-125893:0
Ideal exit: 4 Sept 2023 (T+270)
14,291 shares@ US$1.2643.7% of flowCommon StockSEC:0001104659-22-125503:0
Ideal exit: 2 Sept 2023 (T+270)
35,000 shares@ US$1.7012.8% of flowCommon StockSEC:0001104659-22-099104:0
Ideal exit: 5 Jun 2023 (T+270)
79,000 shares0Common StockSEC:0001104659-22-090246:0
2,221 shares@ US$1.850.0097% mcap4.6% of flowCommon StockSEC:0001104659-22-072979:0
Ideal exit: 13 Mar 2023 (T+270)
16,000 shares@ US$2.1740.082% mcap39.1% of flowCommon StockSEC:0001104659-22-070156:0
Ideal exit: 6 Mar 2023 (T+270)
100 shares@ US$4.040.1% of flowCommon StockSEC:0001104659-22-000566
Ideal exit: 25 Sept 2022 (T+270)
100 shares@ US$4.040.0009% mcap0.4% of flowCommon StockSEC:0001104659-22-000566:0
Ideal exit: 25 Sept 2022 (T+270)
5,000 shares@ US$5.250.058% mcap27.7% of flowCommon StockSEC:0001104659-21-148900:0
Ideal exit: 6 Sept 2022 (T+270)
5,000 shares@ US$5.255.0% of flowCommon StockSEC:0001104659-21-148900
Ideal exit: 6 Sept 2022 (T+270)
18 of 18 declarations
About Chan Phillip P.
Phillip P. Chan is the Chief Executive Officer of Cytosorbents Corp. He is responsible for the overall leadership of the company, which specializes in developing innovative medical technologies. Chan's mission is to guide the company to new heights in research and development while ensuring regulatory compliance and operational efficiency. His leadership is essential for the continued growth and expansion of Cytosorbents.
